CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.45 USD
+0.07 (5.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 121 - 140 ( 152 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our CX-072 Assessment Remains Unchanged Post-ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-072 Update Continues to Support Differentiated Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ESMO 2018 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Slight ORR - G3/4 TRAE Rate Differences for CX-072 Do Not Shake Our Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Leader in Optimizing Checkpoint Inhibition; Initiating at Buy and $32 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; CTMX Expands Comprehensive CX-072 Study; Updated Data at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Update for CX-072; Data Supports Aggressive Development Plan
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-072 Probody Abstracts Report Encouraging Early Data
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; First Look at CTMX Clinical Data in ASCO Abstracts
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.